Tenax Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 11.05 million compared to USD 32.47 million a year ago. Basic loss per share from continuing operations was USD 600.8 compared to USD 2,524.8 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.549 USD | -0.03% | -1.00% | -83.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.84% | 6.95M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B |
- Stock Market
- Equities
- TENX Stock
- News Tenax Therapeutics, Inc.
- Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022